Caribou unveils updated results for allogeneic CAR-T hopeful

2023-07-14

临床1期细胞疗法临床结果免疫疗法抗体药物偶联物

Caribou Biosciences has reported new follow-up data from the dose escalation portion of its ongoing ANTLER Phase I study, which is evaluating the allogeneic anti-CD19 CAR-T therapy CB-010 in 16 patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). Each had received two or more prior lines of chemo-immunotherapy or were primary refractory patients.

Updated results show that 15 of the 16 patients (94%) achieved an overall response rate (ORR) following a single dose of CB-010 and 69% of patients - 11 in the cohort - achieved a complete response (CR). Encouragingly, given that question marks about durability continue to hang over allogeneic CAR-T products, 44% of patients achieved a CR of six months or greater, with 24 months the longest maintained CR to date.

These dose escalation data for CB-010 “rival the responses from autologous cell therapies and demonstrate the potential utility of an off-the-shelf CAR-T cell therapy that could, if approved, provide greater access to patients in need,” said Rachel Haurwitz, Caribou’s president and CEO.

There are some caveats, or at least reasons for caution, however. Data show, for example, that the three patients treated with the highest dose of CB-010 experienced relapse before six months, suggesting that the jury remains out on whether higher dosing allows for more durable responses. Furthermore, the longest ongoing CR is in a patient with follicular lymphoma, which is recognised as a slower growing form of NHL.

Caribou noted that in the cohort of ten patients with large B-cell lymphoma (LBCL) a 90% ORR was observed and 70% of patients achieved a CR, with five patients maintaining this for at least six months. The longest maintained CR in LBCL is 18 months to date, the company added.

Further dose expansion of ANTLER will see the mid- and high-level dose of CB-010 evaluated in approximately 30 second-line patients with LBCLto determine the recommended dosing for a Phase II study, Caribou said. These data will be reported in the first half of 2024.

Pfizer recently made a $25-million equity investment in Caribou, which said it would use the new funds to advance development of another allogeneic CAR-T cell therapy, CB-011, currently in Phase I testing for relapsed or refractory multiple myeloma.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构